BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone
Cell-based immunotherapy program is designed to harness patients’ own immune systemsBria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without
BriaCell hit an important science checkpoint in developing a new cancer vaccine that teaches your body to fight melanoma. When a company reaches milestones like this, it shows progress toward helping patients, though the medicine still needs testing and approval.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.